rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Jasper Therapeutics, Inc.

JSPR · Nasdaq

Health CareBiotechnologyNot moving yet

JSPR stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 29.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
41 (-14)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$334KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0
WhoDidSharesTraded
Patrick J. CrutcherDirectorbought88820 Jul 2026filed 20 Jul 2026
Matthew E. RosChief Operating Officerbought88120 Jul 2026filed 22 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders41-14 on the quarter
New · exited3 · 16
Reported value$4.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Velan Capital Investment Management LPunchanged · filed 14 Aug 20262,668,395$1.1M00.0%
ACORN CAPITAL ADVISORS, LLCadded · filed 14 Aug 20261,438,159$604K+26,667+1.9%
KINGDON CAPITAL MANAGEMENT, L.L.C.unchanged · filed 14 Aug 20261,352,106$569K00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,172,021$493K-5760.0%
Rock Springs Capital Management LPunchanged · filed 14 Aug 20261,100,726$463K00.0%
Carlyle Group Inc.unchanged · filed 7 Aug 20261,066,189$449K00.0%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026486,933$205K-1,130,598−69.9%
Lion Point Capital, LPunchanged · filed 14 Aug 2026465,000$196K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026263,808$111K-53,869−17.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026237,900$100K+60,400+34.0%
31 Dec 2023 – 30 Jun 2026
44077Dec 23Sep 24Mar 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Judith Anne Shizuru Company insiderDirector · last 31 Jul 20261 · 0
Kurt Von Emster Company insiderDirector · last 31 Jul 20260 · 1
Patrick J. Crutcher Company insiderDirector · last 31 Jul 20260 · 0
Svetlana Lucas Company insiderDirector · last 31 Jul 20261 · 0
Thomas G. Wiggans Company insiderDirector · last 31 Jul 20266 · 0
Matthew E. Ros Company insiderChief Operating Officer · last 20 Jul 20260 · 0
Jeetinder Singh Mahal Company insiderCEO and President · last 6 Feb 20260 · 5
Herb Cross Company insiderChief Financial Officer · last 2 Jan 20260 · 0
Ron Martell Company insiderPresident, CEO and Director · last 2 Jan 20261 · 0
Chris Nolet Company insiderDirector · last 3 Jul 20250 · 0
Scott C. Brun Company insiderDirector · last 3 Jul 20250 · 0
Vishal Kapoor Company insiderDirector · last 3 Jul 20250 · 0

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 25 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$28.7M

Analyst forecasts

No analyst forecasts yet.